FL-REVBIO
9.12.2022 20:05:36 CET | Business Wire | Press release
RevBio, Inc., announced that an experiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS). On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceX’s 26th Commercial Resupply Services (SpaceX CRS-26) mission, sponsored by the ISS National Laboratory. This in vivo research, which will be conducted over the next two months on the ISS, will examine the biomaterial’s ability to regenerate bone when used in a microgravity environment where bone growing conditions and the ability to regenerate new bone tissue is significantly compromised.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005635/en/
RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station. This Experiment will Examine TETRANITE’S Ability to Regenerate Bone under the Condition of Microgravity which Simulates Osteoporosis.
Brian Hess, co-inventor of the material and CEO of RevBio said, “This experiment is one of a kind, and will showcase the full potential of this breakthrough technology. The results will both validate and motivate our continued research efforts to commercialize products across several indications aimed at revolutionizing treatment options for patients with osteoporosis who suffer from debilitating fractures and have a poor prognosis for recovery.”
Giuseppe Intini, DDS, PhD, Associate Professor of Periodontics and Preventive Dentistry at the University of Pittsburgh, and faculty member at the McGowan Institute for Regenerative Medicine, has designed the experiment and will oversee its execution. He is supported by his laboratory staff, including Roberta Di Carlo, PhD, a postdoctoral associate who has worked closely with the RevBio team, as well as the ISSNL staff and personnel, RevBio, and the ISS National Lab Implementation Partner, Leidos Innovations Corporation.
This research builds upon a prior in vitro experiment the company conducted on the ISS which measured the biocompatibility and proliferation of osteoblast cells in the presence of Tetranite. Osteoblast cells are responsible for producing new bone in the body. When the company participated in the MassChallenge startup accelerator program, it was awarded a grant for this initial project through the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space, Inc. (CASIS), which manages the ISS National Lab. In this new in vivo experiment, the bone healing process will be examined in live rodents using a calvarial defect model. A side-by-side experiment will be conducted on Earth to examine the differences between healing under both normal and osteoporotic conditions induced by the micro-gravity environment of outer space. By early 2023, additional ISS resupply missions are expected to have returned all of the experimental samples back to Earth where commuted tomography, tissue histology, and gene expression analyses will be conducted to evaluate bone regeneration. Dr. Intini and RevBio are expected to publish the complete results of the experiment by the end of next year.
The research will have a direct impact on RevBio’s commercialization efforts in developing a suite of products to treat bone fractures and defects. In addition to funding for these space-based experiments, RevBio has received considerable grant funding from the National Institute on Aging (2R44AG060881, 1R43AG079741), the National Institute of Neurological Disorders and Stroke (1R44NS115386), and a subaward from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center, funded by the National Institute of Dental and Craniofacial Research (U24-DE029462).
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005635/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISC 2026: KAYTUS Unveils Gigawatt-Scale AI Infrastructure and Intelligent Management to Empower Europe’s AI Future25.6.2026 09:02:00 CEST | Press release
End-to-end, fully factory-prefabricated modular AI Factory deployment in just a few months, with full-stack intelligent management from GPU to rack, to the entire data center. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, unveiled two core solutions at ISC 2026, designed for next-generation AI data centers: a gigawatt-scale, fully prefabricated containerized liquid-cooled data center solution and KSManage Ultra, an intelligent operations management platform for AI Factories. Together, the solutions target the escalating efficiency, performance, scalability, and reliability requirements of AI-era infrastructure, enabling faster deployment, optimized thermal management, and unified operations across large-scale AI computing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625809392/en/ KAYTUS prefabricated containerized liquid cooled data center solution The KAYTUS gigawatt-scale
LR Health & Beauty SE Successfully Completes Financial Realignment – Strong Foundation for Growth and Long-Term Partnerships25.6.2026 09:00:00 CEST | Press release
Successful completion of the financial realignment enables full focus on growth and further strengthening operational excellence Planned investments in production and logistics will enhance efficiency, flexibility, and delivery capabilities Further international growth, including expansion into new markets, targeted LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has successfully completed its financial realignment, establishing the foundation for the company’s stable and forward-looking development. With the achievement of the final milestone, an intensive and demanding process has been successfully concluded. LR has fundamentally realigned its financing structure and significantly strengthened its capital base. An initial financing tranche of EUR 10 million was provided at the end of March, followed by a second tranche of the same amount in June. Jörg Körfer, CEO of LR Health & Beauty SE, comments: “The pas
YesWeHack Launches Agentic Pentest for AI Security Testing25.6.2026 09:00:00 CEST | Press release
New on-demand solution rapidly tests attack surfaces and centralises findings within YesWeHack’s offensive security platform YesWeHack, the offensive security and exposure management platform, announces Agentic Pentest, an on-demand solution using autonomous AI agents to test organisations' assets and deliver same-day findings. Shaped by YesWeHack’s extensive offensive security experience, Agentic Pentest helps organisations identify vulnerabilities, test their real-world exploitability and uncover attack paths across in-scope assets. The solution supports black box, grey box and white box testing of web applications, mobile apps, APIs and other internet-facing assets. YesWeHack, leader in offensive security in Europe and APAC, leverages the best available frontier models for offensive testing, including open-weight models. This flexible approach enables organisations to use models developed and/or hosted anywhere in the world, such as in EU or APAC. Agents operate within guardrails de
H2SITE Secures New Strategic Investment to Accelerate Industrial Deployment of Hydrogen Production and Separation Solutions25.6.2026 06:00:00 CEST | Press release
H2SITE, a leading industrial company in hydrogen production and separation solutions, has completed a second closing of its Series B round. The transaction brings in EIC Fund with a private investor who will support the company’s next phase of growth and increases H2SITE’s total funding raised in this round to more than €42 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624444396/en/ H2SITE These new partners, join BEV, Suma Capital, Hy24, Crane, Enagás Emprende, Calderion and CRPV who participated in the first closing, further validating the confidence of the European innovation ecosystem in H2SITE’s ability to industrialize and deploy key hydrogen solutions at commercial scale. Over the past years, H2SITE has successfully demonstrated the maturity and scalability of its technology, achieving more than 50,000 operating hours with its membrane reactors and separators, establishing advanced manufacturing capabilit
FPT Expands Strategic Collaboration with Microsoft to Advance AI Frontier Innovation Across Asia25.6.2026 04:00:00 CEST | Press release
FPT Corporation today announced an expanded strategic collaboration with Microsoft aimed at accelerating enterprise AI adoption and co‑innovation across Asia, with a strong focus on ASEAN, Japan, and South Korea. The collaboration brings together Microsoft’s global AI platforms with FPT’s large‑scale delivery and regional market capabilities to support organizations as they move from AI experimentation to real‑world, scalable impact, with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624200416/en/ Representatives of FPT and Microsoft at the signing ceremony, formalizing an expanded strategic collaboration to advance AI Frontier innovation across Asia The collaboration aligns with FPT’s AI‑First strategy and Microsoft’s vision for human‑agent collaboration, with the goal of enabling enterprises to redesign how work is done across engineering, operations, and business functions. Positioning FP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom